Eli Lilly news in 2026: 27 dated events
The latest Eli Lilly event on this page is dated Sep 29, 2026. prnewswire.com reported: Lilly's Foundayo (orforglipron) 17.2 mg showed greater weight loss and A1C reduction than oral semaglutide 25 mg among adults with type 2 diabetes in a new indirect treatment...
- Dated events
- 27
- Last 90 days
- 27
- Latest
- Sep 29, 2026
News · latest 10
Latest Eli Lilly news
Showing 10 of 27 dated events. The Signal API returns all of them.
Get them with one API call- Lilly's Foundayo (orforglipron) 17.2 mg showed greater weight loss and A1C reduction than oral semaglutide 25 mg among adults with type 2 diabetes in a new indirect treatment...Eli Lilly and Company is studying its drug Orforglipron as a potential treatment for type 2 diabetes, obstructive sleep apnea, osteoarthritis knee pain, hypertension, peripheral artery disease and stress urinary incontinence.
- Eli Lilly Stock: Bet on OuraEli Lilly, along with Dragoneer Investment Group, is acting as a cornerstone investor in the IPO of sensor ring manufacturer Oura, signaling buying interest of up to $400 million.
- Lilly launches the Lilly Change the Course Commitment, aiming to address treatment gaps in diabetes and obesity in LMICsWith Chugai Pharmaceutical Co., Ltd.
- LLY Stock Rides Trump Spotlight: President Touts Eli Lilly’s $3.5B Factory As Weight-Loss Pill Plans Go GlobalEli Lilly and Company's experimental triple-hormone obesity drug, Retatrutide, is in Phase 3 trials and will be produced at its new Pennsylvania facility.
- Eli Lilly to invest in new plant that will generate 4,600 jobs: here are the available vacancies in TexasEli Lilly is developing Foundayo, a pill for weight control in overweight or obese adults, which will be mass-produced at its new Houston facility.
- Eli Lilly and Company wins FDA pediatric Olumiant approval for severe alopeciaThe U.S. Food and Drug Administration (FDA) has approved an expanded label for Eli Lilly's drug Olumiant, making it a treatment option for adolescents aged 12 and older with severe alopecia areata.
- Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1sEli Lilly held about a 61% share in the U.S. GLP-1 market in the second quarter, compared to Novo's 39%.
- Why we like Starbucks’ latest turnaround move - plus, two more wins for Eli Lilly$3.4B · With InnoCare Pharma
- FDA approval for Lilly’s weekly insulin Onswik, shares dipEli Lilly reported net income of $7.1bn for the second quarter of 2026.
Showing 10 of 27 dated events. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track Eli Lilly with the Signal API
One POST /v1/companies/enrich call with lilly.com returns Eli Lilly news signals (news), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"lilly.com","signal_types":["news"],"limit":20}'Same industry
News at related companies
Questions about Eli Lilly news
What is the latest news on Eli Lilly?
What is going on with Eli Lilly?
Source. News articles about the company, one source link per event.
Method. Stories about the same event within 14 days merge into one row. Noise (lists, stock tips, recaps) is removed.
Data as of .